HIGHLIGHTS
- who: Malvina Koni et al. from the Department of Medical Sciences, University of Turin, Turin, Italy have published the research: Interleukin-3-Receptor- in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target, in the Journal: Cancers 2022, 3918 of 14/Nov/2021
- what: In this study the interleukin-3 receptor α (IL-3Rα) was investigated as a prognostic biomarker and target in IL-3Rα expression and patients' clinical and pathological features were retrospectively analysed in 421 patients. The authors identified IL-3Rα as an additional TNBC prognostic biomarker . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.